Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary Incontinence · Urgency Urinary
Primary: Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu. — 2.192…
Phase 4 N=138 Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Urge Urinary Incontinence
Primary: Baseline Sexual Satisfaction Between Matched Female and Male Partners — 4.2; 4.8 score on a scale — p=.16
N/A N=50 Continence Pessary Versus Disposable Intravaginal Device Trial
Female Stress Incontinence
Primary: Treatment Success — 8; 9 Participants
N/A N=400 Improving Care for Women With Urinary Incontinence (EMPOWER)
Urinary Incontinence
Primary: Change in Patients' UI Symptoms as Measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) — 8.4; 9.0; 9.9; 8.9…
Phase 4 N=645 Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Frequency of Urge Urinary Incontinence Episodes at Week 12. — -2.5; -1.8 episodes — p=<0.001
N/A N=240 A Group-Based Therapeutic Yoga Intervention for Urinary Incontinence in Ambulatory Older Women
Stress Incontinence, Female · Stress Incontinence, Urinary · Stress Incontinence
Primary: Change From Baseline in Total Urinary Incontinence Episodes — -1.99; -1.7 episodes per day — p=0.056
N/A N=61 Mindfulness + tDCS to Reduce Urgency Incontinence in Women
Urinary Incontinence, Urge
Primary: Feasibility of Study Procedures Measured by Percentage of Participants Starting Intervention Who Complete the Study — 100; 90.4; 100 percentage of participants who…
N/A N=70 The Urinary Incontinence Treatment Study
Urinary Incontinence · Sarcopenia
Primary: Number of Urinary Incontinence Episodes — 4.3; 2.7 number of incontinence episodes
N/A N=49 Patient-operated Valved Catheter Versus Indwelling Transurethral Catheter
Bladder Dysfunction · Urinary Retention
Primary: Total Catheter Related Pain — 1.25; 2.3 units on a scale
N/A N=279 Improving Urinary Continence and Quality of Life in Prostate Cancer Patients
Urinary Incontinence
Primary: Amount of Urinary Leakage — 23.2; 22.3; 31.5; 11 grams
N/A N=36 A Randomized Controlled Trial of the Uresta Continence Pessary
Stress Urinary Incontinence
Primary: A 50% Reduction in Pad Test Weight — 12; 4 Participants
N/A N=123 Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women
Urinary Incontinence
Primary: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) — 7.0; 9.8 score on a scale — p=0.001
Phase 4 N=168 Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
Urgency Urinary Incontinence
Primary: Responder (Yes/no) — 23; 39; 36; 17 Participants
Phase 2 N=94 Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence
Urinary Incontinence
Primary: Percentage of Participants With a Decrease in Leakage Events of 30% or More. — 60.6; 61.7 Percentage of participants — p=.92
N/A N=21 Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
N/A N=163 Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
Overactive Bladder
Primary: Evaluate Proportion of Responders Based on the Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups…
N/A N=221 Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence
Urinary Incontinence
Primary: Change of Stamey Grade From Baseline to 12 Months. — -1.17 units on a scale — p=<0.001
N/A N=73 Disposable Stress Urinary Incontinence Pessary Device Study
Stress Urinary Incontinence
Primary: Percentage Reduction of Mean Pad Weight Gain (g/hr) During Treatment Phase as Compared to Baseline Phase. — -47.4 percent change
N/A N=23 Use of the Leva Incontinence System in Treating Bladder Incontinence.
Stress Urinary Incontinence
Primary: Symptoms of Urinary Incontinence at Baseline and at 6 Weeks — 27.5; 1.1 score on a scale — p=0.0001
N/A N=463 Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
Urinary Incontinence, Stress · Urinary Incontinence, Urge
Primary: Group Behavioral Treatment Effectiveness as Shown by Changes From Baseline to 3 Months in Urinary Incontinence Severity. — -2; -1 units on a scale
N/A N=64 Enhancing Conservative Treatment for Urge Incontinence
Urinary Incontinence
Primary: Change in Incontinent Episodes Immediately Post-treatment — -88.5; -78.3 percentage change — p=.16
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
N/A N=18 Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
Overactive Bladder
Primary: Change in Urge Incontinence Episodes — 3.9 UUI
N/A N=208 Conservative Treatment of Postprostatectomy Incontinence
Urinary Incontinence
Primary: Percent Change in Incontinence Episodes on Bladder Diary — 55; 51; 24 % change in episodes per week — p=.001
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Phase 3 N=445 ATLAS: Ambulatory Treatments for Leakage Associated With Stress
Stress Urinary Incontinence · Urinary Incontinence
Primary: "Much Better" or "Very Much Better" on PGI-I at 3 Months — 80; 72; 59 Participants — p=<0.0492